*Molecular and Cellular Biochemistry* **153**: 241–244, 1995.

# Index to Volume 153

Alimard R, *see* Djordjevic C *et al.*
Anand-Srivastava MB, McNeill JH and Yang X-P: Reversal of defective G-proteins and adenylyl cyclase/cAMP signal transduction in diabetic rats by vanadyl sulphate therapy 113–119
Angel JF, *see* Pugazhenti S *et al.*

Baquer NZ, Saxena AK and Srivastava P: Regulation and control of glucose overutilization in erythrocytes by vanadate 157–160
Bevan AP, Drake PG, Yale J-F, Shaver A and Posner BI: Peroxovanadium compounds: Biological actions and mechanism of insulin-mimesis 49–58
Bhanot S, Michoulas A and McNeill JH: Antihypertensive effects of vanadium compounds in hyperinsulinemic, hypertensive rats 205–209
Boissonneault M, Chapdelaine A and Chevalier S: The enhancement by pervanadate of tyrosine phosphorylation on prostatic proteins occurs through the inhibition of membrane-associated tyrosine phosphatases 139–144
Breton E, *see* St-Louis J *et al.*
Brichard SM: Effects of vanadate on the expression of genes involved in fuel homeostasis in animal models of Type I and Type II diabetes 121–124
Brownsey RW and Dong GW: Evidence for selective effects of vanadium on adipose cell metabolism involving actions on cAMP-dependent protein kinase 131–137
Brownsey RW, *see* Pugazhenti S *et al.*
Bruck R, *see* Shechter Y *et al.*

Cadène A, *see* Poucheret P *et al.*
Cam MC, *see* Cros GH *et al.*
Chapdelaine A, *see* Boissonneault M *et al.*
Chevalier S, *see* Boissonneault M *et al.*
Chiasson J-L, *see* Pandey SK *et al.*
Chu Q, *see* Yale JF *et al.*
Crans DC, Mahroof-Tahir M and Keramidas AD: Vanadium chemistry and biochemistry of relevance for use of vanadium compounds as antidiabetic agents 17–24
Cros G, *see* Poucheret P *et al.*
Cros GH, Cam MC, Serrano J-J, Ribes G and McNeill JH: Long-term antidiabetic activity of vanadyl after treatment withdrawal: Restoration of insulin secretion? 191–195
Cruz TF, Morgan A and Min W: *In vitro* and *in vivo* antineoplastic effects of ortrovanadate 161–166

Dabrowiak JC, *see* Hiort C *et al.*
Dahl B, *see* Pugazhenti S *et al.*
Dai S, *see* McNeill JH *et al.*
Deragon G, *see* Fantus IG *et al.*
Dhalla NS, *see* Matsubara T *et al.*
Djordjevic C, Vuletic N, Renslo ML, Puryear BC and Alimard R: Peroxo heteroligand vanadates(V): Synthesis, spectra-structure relationships, and stability toward decomposition 25–29

Domingo JL, Gomez M, Sanchez DJ, Llobet JM and Keen CL: Toxicology of vanadium compounds in diabetic rats: The action of chelating agents on vanadium accumulation 233–240
Dong GW, *see* Brownsey RW *et al.*
Drake PG, *see* Bevan AP *et al.*
Duckworth WC, *see* Hamel FG *et al.*

Elberg G, *see* Shechter Y *et al.*

Fantus IG, Deragon G, Lai Rand Tang S: Modulation of insulin action by vanadate: Evidence of a role for phosphotyrosine phosphatase activity to alter cellular signaling 103–112
Folli F, *see* Goldfine AB *et al.*

Gefel D, *see* Shechter Y *et al.*
Goldfine AB, Simonson DC, Folli F, Patti M-E and Kahn CR: *In vivo* and *in vitro* studies of vanadate in human and rodent diabetes mellitus 217–231
Gomez M, *see* Domingo JL *et al.*
Goodisman J, *see* Hiort C *et al.*
Gross R, *see* Poucheret P *et al.*

Hall DA, *see* Shaver A *et al.*
Hamel FG and Duckworth WC: The relationship between insulin and vanadium metabolism in insulin target tissues 95–102
Hiort C, Goodisman J and Dabrowiak JC: Chemically and photochemically initiated DNA cleavage by an insulin-mimetic *bis*peroxovanadium complex 31–36
Hussain A, *see* Pugazhenti S *et al.*

Kahn CR, *see* Goldfine AB *et al.*
Keen CL, *see* Domingo JL *et al.*
Keramidas AD, *see* Crans DC *et al.*
Khandelwal RL and Pugazhenthi S: *In vivo* effects of vanadate on hepatic glycogen metabolizing and lipogenic enzymes in insulin-dependent and insulin-resistant diabetic animals 87–94
Khandelwal RL, *see* King MJ *et al.*
Khandelwal RL, *see* Pugazhenti S *et al.*
Khandelwal RL, *see* Pugazhenti S *et al.*
King MJ, Pugazhenthi S, Khandelwal RL and Sharma RK: *In vivo* modulation of N-myristoyltransferase activity by orthovanadate 151–155

Lai Rand Tang S, *see* Fantus IG *et al.*
Li J, *see* Shechter Y *et al.*
Llobet JM, *see* Domingo JL *et al.*

Mahroof-Tahir M, *see* Crans DC *et al.*
Mantéguetti M, *see* Poucheret P *et al.*
Matsubara T, Musat-Marcu S, Misra HP and Dhalla NS: Protective effect of vanadate on oxyradical-induced changes in isolated perfused heart 79–85
McNeill JH, *see* Anand-Srivastava MB *et al.*
McNeill JH, *see* Bhanot S *et al.*
McNeill JH, *see* Cros GH *et al.*
McNeill JH, Yuen VG, Dai S and Orvig C: Increased potency of vanadium using organic ligands 175–180

Meyerovitch J, *see* Shechter Y *et al.*
Michoulas A, *see* Bhanot S *et al.*
Miller DS, *see* Shechter Y *et al.*
Min W, *see* Cruz TF *et al.*
Misra HP, *see* Matsubara T *et al.*
Morgan A, *see* Cruz TF *et al.*
Musat-Marcu S, *see* Matsubara T *et al.*

Nardolillo C, *see* Yale JF *et al.*
Ng JB, *see* Shaver A *et al.*

Orvig C, *see* McNeill JH *et al.*

Pandey SK, Chiasson J-L and Srivastava AK: Vanadium salts stimulate mitogen-activated protein (MAP) kinases and ribosomal S6 kinases 69–78
Patti M-E, *see* Goldfine AB *et al.*
Posner BI, *see* Bevan AP *et al.*
Posner BI, *see* Shaver A *et al.*
Posner BI, *see* Yale JF *et al.*
Poucheret P, Gross R, Cadène A, Mantéguetti M, Serrano J-J, Ribes G and Cros G: Long-term correction of STZ-diabetic rats after short-term i.p. $VOSO_4$ treatment: Persistence of insulin secreting capacities assessed by isolated pancreas studies 197–204
Pugazhenthi S, Hussain A, Yu B, Brownsey RW, Angel JF and Khandelwal RL: Vanadate induces normolipidemia and a reduction in the levels of hepatic lipogenic enzymes in obese Zucker rat 211–215
Pugazhenthi S, *see* Khandelwal RL
Pugazhenthi S, *see* King MJ *et al.*
Pugazhenthi S, Tanha F, Dahl B and Khandelwal RL: Decrease in protein tyrosine phosphatase activities in vanadate-treated obese Zucker (fa/fa) rat liver 125–129
Puryear BC, *see* Djordjevic C *et al.*

Renslo ML, *see* Djordjevic C *et al.*
Ribes G, *see* Poucheret P *et al.*
Ribus G, *see* Cros GH *et al.*

Sanchez DJ, *see* Domingo JL *et al.*
Saxena AK, *see* Baquer NZ *et al.*
Scott RE, *see* Wang H
Serrano J-J, *see* Cros GH *et al.*
Serrano J-J, *see* Poucheret P *et al.*
Sharma RK, *see* King MJ *et al.*
Shaver A, Ng JB, Hall DA and Posner BI: The chemistry of peroxovanadium compounds relevant to insulin mimesis 5–15
Shaver A, *see* Bevan AP *et al.*
Shaver A, *see* Yale JF *et al.*
Shechter Y, Li J, Meyerovitch J, Gefel D, Bruck R, Elberg G, Miller DS and Shisheva A: Insulin-like actions of vanadate are mediated in an insulin-receptor-independent manner via non-receptor protein tyrosine kinases and protein phosphotyrosine phosphatases 39–47
Shisheva A, *see* Shechter Y *et al.*
Sicotte B, *see* St-Louis J *et al.*

Simonson DC, *see* Goldfine AB *et al.*
Srivastava AK, *see* Pandey SK *et al.*
Srivastava AK, *see* St-Louis J *et al.*
Srivastava P, *see* Baquer NZ *et al.*
St-Louis J, Sicotte B, Breton E and Srivastava AK: Contractile effects of vanadate on aorta rings from virgin and pregnant rats 145–150

Tanha F, *see* Pugazhenti S *et al.*

Upreti RK: Membrane – vanadium interaction: A toxicokinetic evaluation 167–171

Vigeant C, *see* Yale JF *et al.*
Vuletic N, *see* Djordjevic C *et al.*

Wang H and Scott RE: Unique and selective mitogenic effects of vanadate on SV40-transformed cells 59–67

Yale J-F, *see* Bevan AP *et al.*
Yale JF, Vigeant C, Nardolillo C, Chu Q, Yu J-Z, Shaver A and Posner BI: *In vivo* effects of peroxovanadium compounds in BB rats 181–190
Yang X-P, *see* Anand-Srivastava MB *et al.*
Yu B, *see* Pugazhenti S *et al.*
Yu J-Z, *see* Yale JF *et al.*
Yuen VG, *see* McNeill JH *et al.*